Effects of statins in patients with coronary artery spasm: A nationwide population‐based study

• Published in: Clinical and translational science 2024-11, Vol.17 (11), p.e70087-n/a
• Main Authors: Lee, Yu‐Ching, Hung, Ming‐Jui, Chen, Tien‐Hsing, Mao, Chun‐Tai, Yeh, Chi‐Tai, Kounis, Nicholas G., Chen, Ian Y., Hu, Patrick, Hung, Ming‐Yow
• Format: Article
• Language: English
• Subjects: Adult; Aged; Cardiovascular disease; Cardiovascular diseases; Chronic obstructive pulmonary disease; Coronary artery disease; Coronary Vasospasm - drug therapy; Coronary Vasospasm - epidemiology; Databases, Factual; Diabetes mellitus; Drug dosages; Dyslipidemia; Female; Heart diseases; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Ischemia; Male; Middle Aged; Mortality; Patients; Population studies; Propensity Score; Retrospective Studies; Risk Factors; Statins; Stroke; Taiwan - epidemiology; Treatment Outcome
• ISSN: 1752-8054; 1752-8062; 1752-8062
• DOI: 10.1111/cts.70087

Controversies regarding the benefits of statin treatment on clinical outcomes in coronary artery spasm (CAS) without obstructive coronary artery disease (CAD) persist due to limited data. In this retrospective nationwide population‐based cohort study from the Taiwan National Health Insurance Research Database during the period 2000–2012, the matched cohorts consisted of 12,000 patients with CAS. After propensity score matching with 1:1 ratio, 2216 patients were eligible for outcome analysis in either statin or nonstatin group, with the mean follow‐up duration of 4.8 and 4.6 years, respectively. Statin users versus nonusers had a significantly reduced risk of major adverse cardiovascular events (MACEs) (6.7% vs. 9.5%, hazard ratio [HR] 0.68; 95% confidence interval [CI] 0.55–0.84) and all‐cause mortality (6.0% vs. 7.6%; HR 0.77; 95% CI 0.61–0.96). While the results of MACEs were mainly contributed by cardiovascular death (1.9% vs. 3.2%; HR 0.56; 95% CI 0.38–0.83) and ischemic stroke (3.8% vs. 5.4%; subdistribution HR 0.69; 95% CI 0.52–0.91), they were primarily driven by reductions in ischemic but not hemorrhagic stroke. The benefit of statins was significantly pronounced in patients with hypertension and diabetes. Nevertheless, the effect on MACEs was consistent irrespective of age, sex, dyslipidemia, and mental disorder. Statins significantly reduced the risk of MACEs and all‐cause mortality in CAS patients. The benefit of statin therapy in reducing MACEs appeared to be linear, with greater risk reduction with higher doses and longer duration without upper threshold, reflecting the dose‐dependent relationship of statins with MACEs in CAS patients. In this retrospective nationwide population‐based cohort study from the Taiwan National Health Insurance Research Database during the period 2000–2012, the matched cohorts consisted of 12,000 patients with CAS. After propensity score matching with 1:1 ratio, 2216 patients were eligible for outcome analysis in either statin or nonstatin group, with the mean follow‐up duration of 4.8 and 4.6 years, respectively. Statin users versus nonusers had a significantly reduced risk of MACEs (6.7% vs. 9.5%), which were mainly contributed by reduced cardiovascular death and ischemic stroke but not hemorrhagic stroke. The benefit of statin therapy appeared to be linear, with greater risk reduction with higher doses and longer duration without upper threshold, reflecting the dose‐dependent relationship of statins with MACEs in